Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.

Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE, Abraham I.

Cancer Med. 2016 Jul;5(7):1481-91. doi: 10.1002/cam4.732. Epub 2016 May 11.

2.

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.

Yun S, Vincelette ND, Knorr KL, Almada LL, Schneider PA, Peterson KL, Flatten KS, Dai H, Pratz KW, Hess AD, Smith BD, Karp JE, Hendrickson AE, Fernandez-Zapico ME, Kaufmann SH.

Blood. 2016 Jun 2;127(22):2711-22. doi: 10.1182/blood-2015-02-629485. Epub 2016 Feb 25.

3.

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.

Wahner Hendrickson AE, Hawthorne KM, Goode EL, Kalli KR, Goergen KM, Bakkum-Gamez JN, Cliby WA, Keeney GL, Visscher DW, Tarabishy Y, Oberg AL, Hartmann LC, Maurer MJ.

Gynecol Oncol. 2015 Apr;137(1):77-85. doi: 10.1016/j.ygyno.2015.01.539. Epub 2015 Jan 22.

4.

A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients.

Jatoi A, Radecki Breitkopf C, Foster NR, Block MS, Grudem M, Wahner Hendrickson A, Carlson RE, Barrette B, Karlin N, Fields AP.

Oncology. 2015;88(4):208-13. doi: 10.1159/000369257. Epub 2014 Dec 6.

5.

ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.

Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.

Cancer Res. 2013 Jun 15;73(12):3683-91. doi: 10.1158/0008-5472.CAN-13-0110. Epub 2013 Apr 2.

6.

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.

Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C.

Invest New Drugs. 2013 Oct;31(5):1251-6. doi: 10.1007/s10637-013-9946-7. Epub 2013 Mar 31.

7.

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.

Gupta M, Hendrickson AE, Yun SS, Han JJ, Schneider PA, Koh BD, Stenson MJ, Wellik LE, Shing JC, Peterson KL, Flatten KS, Hess AD, Smith BD, Karp JE, Barr S, Witzig TE, Kaufmann SH.

Blood. 2012 Jan 12;119(2):476-87. doi: 10.1182/blood-2011-04-346601. Epub 2011 Nov 11.

8.

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P.

Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1.

9.

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

Wahner Hendrickson AE, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar R, Smith BD, Erlichman C, Gottardis M, Karp JE, Carboni JM, Kaufmann SH.

Cancer Res. 2009 Oct 1;69(19):7635-43. doi: 10.1158/0008-5472.CAN-09-0511. Epub 2009 Sep 29.

Supplemental Content

Loading ...
Support Center